Melanne Rosetta, OD
Optometrist · Iselin, NJNPI 1265954200
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,811 of the $65,988 with a category attached, or 61.8%. Mallinckrodt Hospital Products Inc. accounts for 70.0% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $37,742, more than ten times the $840 reported in 2019. Among optometrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $175.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$46K
- Biotissue Holdings Inc.$9K
- Glaukos Corporation$3K
- AbbVie$1K
- Alcon$1K
- Bausch & Lomb Americas Inc.$844
- plus $5K from 20 others
What the payments were for
- Consulting fees$1,0002%
- Speaking & faculty fees$40,81162%
- Travel & lodging$9,14014%
- Food & beverage$14,79922%
- Education$1980%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 86 | $46,208 |
| Biotissue Holdings Inc. | 46 | $8,534 |
| Glaukos Corporation | 38 | $3,386 |
| AbbVie(2 entities) | 25 | $1,203 |
| Alcon | 42 | $1,025 |
| Bausch & Lomb Americas Inc. | 13 | $844 |
| Rxsight Inc | 12 | $755 |
| Dompe US, Inc. | 21 | $693 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $610 |
| Tarsus Pharmaceuticals, Inc. | 20 | $485 |
| Harrow Eye, LLC | 18 | $385 |
| Sight Sciences, Inc. | 4 | $377 |
| NEW World Medical,inc. | 2 | $233 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $228 |
| Oyster Point Pharma, Inc. | 12 | $216 |
| Sanofi | 2 | $191 |
| Novartis | 3 | $119 |
| Sun Pharmaceutical Industries Inc. | 5 | $99 |
| Ivantis, Inc | 1 | $92 |
| Topcon Healthcare, Inc. | 1 | $91 |
| Kala Pharmaceuticals, Inc. | 3 | $58 |
| Amgen | 3 | $47 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Thea Pharma Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$45,040
- Prokera$4,197
- AmnioGraft$1,278
- iStent inject Trabecular Micro-Bypass Stent System$1,054
- Photrexa$942
- enVista MX60 IOL$735
- KXL System$678
- RXSIGHT INJECTOR HANDPIECE$656
- RXSIGHT CONTACT LENS$656
- LIGHT ADJUSTABLE LENS (LAL)$656
- RXSIGHT INJECTOR CARTRIDGE$656
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$656
- iStent inject W$562
- XEN GLAUCOMA TREATMENT SYSTEM$507
- Clareon$429
- Oxervate$374
- Tecnis IOL$347
- Kahook Dual Blade$189
- Clearpath$189
- Ahmed Glaucoma Valve$189
How this compares
$65,988 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 44 | $55,351 |
| XdemvyLotilaner | 23 | $43,368 |
| RestasisCyclosporine | 14 | $13,116 |
| VyzultaLatanoprostene Bunod | 20 | $9,396 |
| LumiganBimatoprost | 12 | $8,232 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $6,197 |
| Prednisolone Acetate | 118 | $4,154 |
| Timolol Maleate | 106 | $3,012 |
| Latanoprost | 175 | $1,985 |
| Doxycycline Hyclate | 15 | $1,837 |
| Loteprednol Etabonate | 12 | $1,342 |
| Travoprost | 15 | $1,008 |
| MoxifloxacinMoxifloxacin Hcl | 50 | $997 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 55 | $805 |
| Ketorolac Tromethamine | 42 | $784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $844 | $64,74764 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $485 | $43,36823 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,203 | $27,54638 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $228 | $1,34212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in Iselin
- Eric DevoreIselin$17K
- Muhammad ShahbakhtIselin$13K
- Natalie NguyenIselin$10K
- Michael VelikyIselin$6K
- Frances TsaiIselin$6K
- Carly CrapanzanoIselin$6K
- Kerry GelbWoodbridge$264K
- Rodolfo RodriguezNorth Bergen$244K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.